Share on StockTwits

Myriad Genetics (NASDAQ:MYGN) posted its quarterly earnings results on Tuesday. The company reported $0.48 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.46 by $0.02, Analyst RN reports. The company had revenue of $188.80 million for the quarter, compared to the consensus estimate of $187.68 million.

MYGN has been the subject of a number of recent research reports. Analysts at SunTrust raised their price target on shares of Myriad Genetics from $22.00 to $26.00 in a research note on Monday, July 14th. On a related note, analysts at RBC Capital raised their price target on shares of Myriad Genetics from $31.00 to $40.00 in a research note on Monday, June 30th. They now have a “sector perform” rating on the stock. Finally, analysts at Macquarie reiterated a “neutral” rating on shares of Myriad Genetics in a research note on Thursday, June 5th. They now have a $36.00 price target on the stock, down previously from $38.00. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $35.34.

Myriad Genetics (NASDAQ:MYGN) traded up 2.04% on Tuesday, hitting $39.05. The stock had a trading volume of 1,731,578 shares. Myriad Genetics has a 52 week low of $20.02 and a 52 week high of $42.50. The stock has a 50-day moving average of $37.69 and a 200-day moving average of $35.9. The company has a market cap of $2.922 billion and a P/E ratio of 16.23.

Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.